Nā maʻi neurodegenerative(NDDs) i hōʻike ʻia e ka holomua a i ʻole ka hoʻomau mau ʻana o nā heluna neuronal vulnerable i loko o ka lolo a i ʻole ke kuamoʻo. Hiki ke hoʻokumu ʻia ka hoʻokaʻawale ʻana o nā NDD ma luna o nā pae like ʻole, me ka mahele anatomical o neurodegeneration (e like me nā maʻi extrapyramidal, frontotemporal degeneration, a i ʻole spinocerebellar ataxias), nā mea kūlohelohe mua (e like me amyloid-β, prions, tau, a i ʻole α-synuclein), a i ʻole nā hiʻohiʻona nui (e like me ka maʻi Parkinsonic lateral, amyoclerosis). ʻOiai kēia mau ʻokoʻa i ka hoʻokaʻawale ʻana a me ka hōʻike ʻana i nā hōʻailona, nā maʻi e like me ka maʻi Parkinson (PD), Amyotrophic Lateral Sclerosis (ALS), a me ka maʻi Alzheimer (AD) kaʻana like i nā kaʻina hana maʻamau e alakaʻi ana i ka neuronal dysfunction a me ka hopena o ka make cell.
Me nā miliona o ka honua i hoʻopilikia ʻia e NDDs, ua manaʻo ka World Health Organization i ka makahiki 2040, e lilo kēia mau maʻi i kumu lua o ka make ma nā ʻāina hoʻomohala. ʻOiai aia nā lāʻau lapaʻau like ʻole e hoʻēmi a mālama i nā hōʻailona e pili ana i nā maʻi kikoʻī, ʻo nā ala kūpono e hoʻolōʻihi a hoʻōla paha i ka holomua o kēia mau maʻi e paʻa mau. Hōʻike nā haʻawina hou i ka hoʻololi ʻana i nā paradigms lapaʻau mai ka hoʻokele symptomatic wale nō i ka hoʻohana ʻana i nā mīkini pale cell e pale ai i ka pōʻino hou aʻe. Hōʻike nā hōʻike nui i ke koʻikoʻi o ka oxidative a me ka mumū i nā hana koʻikoʻi i ka neurodegeneration, e hoʻonoho ana i kēia mau mīkini i mea koʻikoʻi no ka pale ʻana i ka cellular. I nā makahiki i hala iho nei, ua hōʻike ka noiʻi kumu a me ka noiʻi lapaʻau i ka hiki o ka Hyperbaric Oxygen Therapy (HBOT) i ka mālama ʻana i nā maʻi neurodegenerative.
Ka hoʻomaopopo ʻana i ka Hyperbaric Oxygen Therapy (HBOT)
Hoʻokomo maʻamau ka HBOT i ka hoʻonui ʻana i ke kaomi ma luna o 1 absolute ea (ATA) - ke kaomi ma ka ʻilikai - no ka lōʻihi o 90-120 mau minuke, koi pinepine i nā kau he nui ma muli o ke kūlana kikoʻī e mālama ʻia. ʻO ka hoʻonui ʻia ʻana o ka ea e hoʻomaikaʻi i ka hāʻawi ʻana i ka oxygen i nā cell, kahi e hoʻoulu ai i ka hoʻonui ʻana o nā cell stem a hoʻonui i nā kaʻina hoʻōla i hoʻopili ʻia e kekahi mau mea ulu.
Ma mua, ua hoʻokumu ʻia ka noi ʻana o HBOT ma ke kānāwai Boyle-Marriott, ka mea e hōʻemi ana i ka hoʻohaʻahaʻa ʻana i ke kaomi ʻana o nā ʻōpū kinoea, me nā pōmaikaʻi o nā pae oxygen kiʻekiʻe i loko o nā kiko. Aia kekahi ʻano o nā pathologies i ʻike ʻia e pōmaikaʻi mai ka mokuʻāina hyperoxic i hana ʻia e HBOT, me nā ʻiʻo necrotic, nā ʻeha radiation, trauma, kuni, compartment syndrome, a me gas gangrene, a me nā mea ʻē aʻe i helu ʻia e ka Undersea and Hyperbaric Medical Society. ʻO ka mea nui, ua hōʻike ʻo HBOT i ka maikaʻi ma ke ʻano he lāʻau hoʻohui i nā ʻano maʻi ʻeha a i ʻole nā maʻi maʻi, e like me ka colitis a me ka sepsis. Hāʻawi ʻia i kāna mau hana anti-inflammatory a me ka oxidative, hāʻawi ʻo HBOT i ka mana koʻikoʻi ma ke ʻano he ala lapaʻau no nā maʻi neurodegenerative.
Nā Haʻawina Preclinical o Hyperbaric Oxygen Therapy i nā maʻi Neurodegenerative: Nā ʻike mai ka 3×Tg Mouse Model
ʻO kekahi o nā haʻawina kaulanai kālele ʻia i ka 3×Tg kiʻi ʻiole o ka maʻi o Alzheimer (AD), ka mea i hōʻike i ka therapeutic hiki o HBOT i ka hoʻomaikaʻi ʻana i nā hemahema cognitive. Ua pili ka noiʻi ʻana i nā ʻiole kāne 3×Tg 17 mau mahina i hoʻohālikelike ʻia me 14 mau mahina kāne C57BL/6 mau ʻiole e lawelawe ana ma ke ʻano he mana. Ua hōʻike ʻia ka haʻawina ʻaʻole i hoʻomaikaʻi wale ʻo HBOT i ka hana cognitive akā ua hoʻemi nui ʻia ka mumū, ka ukana plaque, a me Tau phosphorylation-he kaʻina hana koʻikoʻi e pili ana me AD pathology.
ʻO nā hopena pale o ka HBOT i pili i ka emi ʻana o ka neuroinflammation. Ua hōʻike ʻia kēia ma ka hōʻemi ʻana o ka microglial proliferation, astrogliosis, a me ka huna ʻana o nā cytokines pro-inflammatory. Hōʻike kēia mau ʻike i ka hana ʻelua o HBOT i ka hoʻonui ʻana i ka hana cognitive aʻo ka hoʻēmi ʻana i nā kaʻina neuroinflammatory e pili ana i ka maʻi o Alzheimer.
ʻO kekahi kumu hoʻohālike preclinical i hoʻohana i nā ʻiole 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) e loiloi i nā hana pale o HBOT ma ka hana neuronal a me nā mana kaʻa. Ua hōʻike ʻia nā hopena ua hāʻawi ʻo HBOT i ka hoʻoikaika ʻana i ka hana kaʻa a me ka ikaika paʻa i kēia mau ʻiole, e hoʻopili ana me ka piʻi ʻana o ka hōʻailona biogenesis mitochondrial, ma o ka hoʻāla ʻana o SIRT-1, PGC-1α, a me TFAM. Hōʻike kēia i ka hana nui o ka hana mitochondrial i nā hopena neuroprotective o HBOT.
Nā Mechanisms o HBOT i nā maʻi Neurodegenerative
ʻO ke kumu kumu o ka hoʻohana ʻana i ka HBOT no nā NDD aia i ka pilina ma waena o ka hāʻawi ʻana i ka oxygen a me ka maʻalahi i nā loli neurodegenerative. ʻO ka Hypoxia-inducible factor-1 (HIF-1) he kuleana koʻikoʻi ma ke ʻano he transcription factor e hiki ai i ka hoʻololi ʻana i ke kelepona i ka haʻahaʻa o ka oxygen haʻahaʻa a ua hoʻopili ʻia i nā NDD like ʻole me AD, PD, Huntington's Disease, a me ALS, e hōʻailona ana iā ia ma ke ʻano he lāʻau lapaʻau koʻikoʻi.
Ma muli o ka makahiki he kumu koʻikoʻi koʻikoʻi no nā maʻi neurodegenerative he nui, he mea nui ka noiʻi ʻana i ka hopena o ka HBOT i ka neurobiology kahiko. Ua hōʻike ʻia nā haʻawina e hiki i ka HBOT ke hoʻomaikaʻi i nā hemahema cognitive pili i ka makahiki i nā kumuhana olakino olakino.Eia hou, ua hōʻike ʻia nā poʻe maʻi ʻelemakule me nā hemahema hoʻomanaʻo koʻikoʻi i ka hoʻomaikaʻi ʻana i ka cognitive a me ka hoʻonui ʻana i ke kahe koko cerebral ma hope o ka ʻike ʻana iā HBOT.
1. Ka hopena o ka HBOT ma luna o ka ho'ā a me ke koʻikoʻi oxidative
Ua hōʻike ʻo HBOT i ka hiki ke hoʻohaʻahaʻa i ka neuroinflammation i nā poʻe maʻi me ka lolo koʻikoʻi. Loaʻa iā ia ka hiki ke hoʻohaʻahaʻa i nā cytokine pro-inflammatory (e like me IL-1β, IL-12, TNFα, a me IFNγ) i ka wā e hoʻoponopono ai i nā cytokine anti-inflammatory (e like me IL-10). Ke manaʻo nei kekahi poʻe noiʻi ʻo ka reactive oxygen species (ROS) i hana ʻia e HBOT e hoʻopili i nā hopena maikaʻi o ka lāʻau. No laila, ma waho aʻe o kāna hana hoʻohaʻahaʻa puʻupuʻu e pili ana i ke kaomi a me ka loaʻa ʻana o ka saturation oxygen kiʻekiʻe, ʻo nā hopena maikaʻi e pili ana i ka HBOT e pili ana i nā kuleana physiological o ka ROS i hana ʻia.
2. Nā hopena o ka HBOT ma ka Apoptosis a me ka Neuroprotection
Ua hōʻike ʻia ka noiʻi hiki i ka HBOT ke hōʻemi i ka phosphorylation hippocampal o p38 mitogen-activated protein kinase (MAPK), a laila hoʻomaikaʻi i ka cognition a me ka hōʻemi ʻana i ka pōʻino hippocampal. ʻO ka HBOT kūʻokoʻa a me ka hui pū ʻana me Ginkgo biloba extract ua ʻike ʻia e hoʻohaʻahaʻa i ka hōʻike ʻana o Bax a me ka hana o caspase-9/3, ka hopena i ka emi ʻana o nā apoptosis i nā ʻano rodent i hoʻokomo ʻia e aβ25-35. Eia kekahi, ua hōʻike ʻia kahi noiʻi ʻē aʻe i ka HBOT preconditioning induced tolerance e kūʻē i ka cerebral ischemia, me nā hana e pili ana i ka hoʻonui ʻana i ka SIRT1 expression, me ka hoʻonui ʻana i nā pae B-cell lymphoma 2 (Bcl-2) a hoʻemi i ka caspase-3 ikaika, e hōʻike ana i ka neuroprotective a me nā waiwai anti-apoptotic o HBOT.
3. Ka hopena o ka HBOT ma ka Circulation aNeurogenesis
ʻO ka hōʻike ʻana i nā kumuhana i ka HBOT ua pili pū me nā hopena he nui i ka ʻōnaehana vascular cranial, me ka hoʻonui ʻana i ke kahe o ka pale koko-lolo, ka hoʻoulu ʻana i ka angiogenesis, a me ka hōʻemi ʻana i ka edema. Ma waho aʻe o ka hāʻawi ʻana i nā lako oxygen hoʻonui i nā kiko, HBOThoʻoulu i ka hoʻokumu ʻana o nā vascularma ka hoʻoulu ʻana i nā mea transcription e like me ka vascular endothelial growth factor a me ka hoʻoulu ʻana i ka hoʻonui ʻana o nā pūnaewele neural stem.
4. Nā hopena Epigenetic o HBOT
Ua hōʻike ʻia nā haʻawina ʻo ka hoʻolaha ʻana o ke kanaka microvascular endothelial cell (HMEC-1) i ka oxygen hyperbaric e hoʻoponopono nui i nā genes 8,101, me nā ʻōlelo upregulated a hoʻohaʻahaʻa ʻia, e hōʻike ana i ka piʻi ʻana o ka hōʻike gen e pili ana i nā ala pane antioxidant.
Ka hopena
ʻO ka hoʻohana ʻana i ka HBOT ua hana nui i ka manawa, e hōʻike ana i kona loaʻa, hilinaʻi, a me ka palekana i ka hana lapaʻau. ʻOiai ua ʻimi ʻia ʻo HBOT ma ke ʻano he lāʻau lapaʻau ma waho o ka inoa no nā NDD a ua mālama ʻia kekahi mau noiʻi, aia nō kahi koi koi no nā noiʻi ikaika e hoʻohālikelike i nā hana HBOT i ka mālama ʻana i kēia mau kūlana. Pono nā noiʻi hou aʻe e hoʻoholo i nā alapine lapaʻau maikaʻi loa a nānā i ka nui o nā hopena maikaʻi no nā maʻi.
I ka hōʻuluʻulu ʻana, ʻo ka intersection o hyperbaric oxygen a me nā maʻi neurodegenerative e hōʻike ana i kahi palena hoʻohiki i nā hiki therapeutic, e hōʻoiaʻiʻo ana i ka hoʻomau ʻana i ka ʻimi a me ka hōʻoia ʻana i nā hoʻonohonoho lapaʻau.
Ka manawa hoʻouna: Mei-16-2025